Loading...

Analytica

ASX:ALT
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALT
ASX
A$13M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
  • Analytica has significant price volatility in the past 3 months.
ALT Share Price and Events
7 Day Returns
-11.1%
ASX:ALT
0.7%
AU Medical Equipment
1.7%
AU Market
1 Year Returns
-42.9%
ASX:ALT
-1%
AU Medical Equipment
5.9%
AU Market
ALT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Analytica (ALT) -11.1% 0% -20% -42.9% -33.3% -87.1%
AU Medical Equipment 0.7% 3.1% 0.1% -1% 44.1% 106.9%
AU Market 1.7% 4% 8.6% 5.9% 21.4% 7.4%
1 Year Return vs Industry and Market
  • ALT underperformed the Medical Equipment industry which returned -1% over the past year.
  • ALT underperformed the Market in Australia which returned 5.9% over the past year.
Price Volatility
ALT
Industry
5yr Volatility vs Market

Value

 Is Analytica undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Analytica. This is due to cash flow or dividend data being unavailable. The share price is A$0.004.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Analytica's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Analytica's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ALT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:ALT Share Price ** ASX (2019-04-24) in AUD A$0
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.76x
Australia Market PE Ratio Median Figure of 543 Publicly-Listed Companies 16.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Analytica.

ASX:ALT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ALT Share Price ÷ EPS (both in AUD)

= 0 ÷ 0.00

-6.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Analytica is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Analytica is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Analytica's expected growth come at a high price?
Raw Data
ASX:ALT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.36x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Analytica, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Analytica's assets?
Raw Data
ASX:ALT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.00
ASX:ALT Share Price * ASX (2019-04-24) in AUD A$0
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.78x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.66x
ASX:ALT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ALT Share Price ÷ Book Value per Share (both in AUD)

= 0 ÷ 0.00

9.76x

* Primary Listing of Analytica.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Analytica is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Analytica's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Analytica has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Analytica expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Analytica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Analytica expected to grow at an attractive rate?
  • Unable to compare Analytica's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Analytica's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Analytica's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:ALT Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.8%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ALT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ALT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -2 -2
2018-09-30 1 -2 -2
2018-06-30 1 -2 -2
2018-03-31 1 -3 -3
2017-12-31 0 -3 -4
2017-09-30 1 -3 -4
2017-06-30 1 -2 -3
2017-03-31 1 -2 -3
2016-12-31 1 -1 -4
2016-09-30 2 -3 -4
2016-06-30 2 -4 -4
2016-03-31 2 -5 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Analytica is high growth as no earnings estimate data is available.
  • Unable to determine if Analytica is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ALT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Analytica Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ALT Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00
2016-06-30 0.00
2016-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Analytica will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Analytica's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Analytica's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Analytica's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Analytica's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Analytica has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Analytica performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Analytica's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Analytica does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Analytica's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Analytica's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Analytica's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Analytica Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ALT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.98 -1.89 1.16
2018-09-30 0.99 -2.02 1.24
2018-06-30 1.00 -2.16 1.32
2018-03-31 0.54 -3.11 1.50
2017-12-31 0.09 -4.06 1.68
2017-09-30 0.66 -3.66 1.87
2017-06-30 1.24 -3.25 2.06
2017-03-31 1.25 -3.43 2.21
2016-12-31 1.26 -3.60 2.36
2016-09-30 1.68 -3.74 2.71
2016-06-30 2.10 -3.88 3.06
2016-03-31 2.10 -4.24 3.19
2015-12-31 2.10 -4.61 3.32
2015-09-30 1.59 -4.96 3.06
2015-06-30 1.07 -5.32 2.79
2015-03-31 1.32 -4.52 2.38
2014-12-31 1.56 -3.73 1.97
2014-09-30 1.06 -3.45 1.70
2014-06-30 0.57 -3.18 1.43
2014-03-31 0.53 -2.49 1.17
2013-12-31 0.50 -1.80 0.90
2013-09-30 0.51 -1.47 0.67
2013-06-30 0.51 -1.14 0.45
2013-03-31 0.34 -1.23 0.47 0.25
2012-12-31 0.16 -1.31 0.50 0.51
2012-09-30 0.16 -1.77 0.50 0.71
2012-06-30 0.16 -2.22 0.49 0.91

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Analytica has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Analytica has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Analytica improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Analytica's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Analytica has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Analytica's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Analytica's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Analytica is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Analytica's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Analytica's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Analytica has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Analytica Company Filings, last reported 3 months ago.

ASX:ALT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1.37 0.00 1.47
2018-09-30 1.37 0.00 1.47
2018-06-30 2.85 0.00 2.84
2018-03-31 2.85 0.00 2.84
2017-12-31 0.73 0.00 0.80
2017-09-30 0.73 0.00 0.80
2017-06-30 1.21 0.00 1.21
2017-03-31 1.21 0.00 1.21
2016-12-31 1.23 0.00 1.23
2016-09-30 1.23 0.00 1.23
2016-06-30 1.30 0.00 1.25
2016-03-31 1.30 0.00 1.25
2015-12-31 1.75 0.28
2015-09-30 1.75 0.28
2015-06-30 0.38 0.00 0.58
2015-03-31 0.38 0.00 0.58
2014-12-31 3.81 0.00 3.43
2014-09-30 3.81 0.00 3.43
2014-06-30 2.37 0.01 1.96
2014-03-31 2.37 0.01 1.96
2013-12-31 1.26 0.00 1.42
2013-09-30 1.26 0.00 1.42
2013-06-30 0.17 0.00 0.35
2013-03-31 0.17 0.00 0.35
2012-12-31 0.59 0.00 0.61
2012-09-30 0.59 0.00 0.61
2012-06-30 1.30 0.00 1.21
  • Analytica has no debt.
  • Analytica had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Analytica has less than a year of cash runway based on current free cash flow.
  • Analytica has less than a year of cash runway if free cash flow continues to reduce at historical rates of -32.2% each year.
X
Financial health checks
We assess Analytica's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Analytica has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Analytica's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Analytica dividends.
If you bought A$2,000 of Analytica shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Analytica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Analytica's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ALT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Analytica has not reported any payouts.
  • Unable to verify if Analytica's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Analytica's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Analytica has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Analytica's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Analytica afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Analytica has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Analytica's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Geoff Daly
COMPENSATION A$240,900
TENURE AS CEO 5.2 years
CEO Bio

Mr. Geoff Daly, BE (Hons, Mech, UQ), MBA (Exec, AGSM), MIEAust CPEng (Mech, Biomed), MAICD has been the Chief Executive Officer of Analytica Ltd. since February 12, 2014. Mr. Daly served as the Chief Operating Officer of Analytica Ltd. until February 12, 2014 and also served as its Operations Manager since November 7, 2005. He has extensive experience in the design of medical devices, prototyping and manufacturing. He has almost 20 years experience in medical device companies with an emphasis on product development, commercialisation, regulatory affairs and quality assurance within the sector. He has managed production and supply chain elements for successfully commercialised technologies while also crossing over into strategic advice and implementation. Mr. Daly spent over seven years with multi-billion dollar medical devices company ResMed Inc in Sydney. He served in senior engineering and project management roles with responsibility for the upkeep of products released to the market and earlier for the mechanical engineering aspects of Flow Generator products. Mr. Daly graduated from the University of Queensland with a Bachelor of Engineering with first class honours. He is a member of AusBiotech, the Australian Institute of Company Directors and a Chartered Professional Engineer in both Mechanical and Biomedical Engineering. He has since completed an Executive MBA at the Australian Graduate School of Management.

CEO Compensation
  • Geoff's compensation has been consistent with company performance over the past year.
  • Geoff's remuneration is lower than average for companies of similar size in Australia.
Management Team

Michael Monsour

TITLE
Executive Chairman
COMPENSATION
A$82K

Geoff Daly

TITLE
Chief Executive Officer
COMPENSATION
A$241K
TENURE
5.2 yrs

Ross Mangelsdorf

TITLE
CFO & Executive Director
COMPENSATION
A$211K

Chelsea Cornelius

TITLE
Product Development & Operations Manager

Megan Henken

TITLE
Vice President of Global Marketing

Bryan Dulhunty

TITLE
Company Secretary
COMPENSATION
A$19K
TENURE
6.5 yrs
Board of Directors Tenure

Average tenure of the Analytica board of directors in years:

7.1
Average Tenure
  • The tenure for the Analytica board of directors is about average.
Board of Directors

Michael Monsour

TITLE
Executive Chairman
COMPENSATION
A$82K
TENURE
14.8 yrs

Ross Mangelsdorf

TITLE
CFO & Executive Director
COMPENSATION
A$211K
TENURE
10.5 yrs

Thomas Lönngren

TITLE
Non-Executive Director
COMPENSATION
A$57K
TENURE
3.7 yrs

Peter Corr

TITLE
Non-Executive Director
COMPENSATION
A$73K
AGE
70
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Analytica's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Analytica has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Of Analytica Limited (ASX:ALT) Do Insiders Own?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Analytica is a smaller company with a market capitalization of AU$13m, so it may still be flying under the radar of many institutional investors. … institutions don't own shares in the company

Simply Wall St -

Imagine Owning Analytica And Trying To Stomach The 83% Share Price Drop

Spare a thought for anyone who held Analytica Limited (ASX:ALT) for five whole years - as the share price tanked 83%. … Unhappily, the share price slid 20% in the last week. … With the share price down 30% per year, over 5 years, it seems likely that the need for cash is weighing on investors' minds

Simply Wall St -

Is Analytica Limited (ASX:ALT) A Financially Sound Company?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Is Analytica Limited's (ASX:ALT) CEO Paid At A Competitive Rate?

In 2014 Geoff Daly was appointed CEO of Analytica Limited (ASX:ALT). … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Geoff Daly's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Should You Wait Before Investing In Analytica Limited (ASX:ALT)?

The single most important question to ask when you’re investing in a loss-making company is – will they need to raise cash again, and if so, when? … Cash is crucial to run a business, and if a company burns through its reserves fast, it will need to come back to market for additional capital raising. … Looking at Analytica’s latest financial data, I will gauge when the company may run out of cash and need to raise more money.

Simply Wall St -

Does Analytica Limited (ASX:ALT) Have A Particularly Volatile Share Price?

Volatility is considered to be a measure of risk in modern finance theory. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What You Must Know About Analytica Limited's (ASX:ALT) Financial Strength

The direct benefit for Analytica Limited (ASX:ALT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Why You Need To Look At This Factor Before Buying Analytica Limited (ASX:ALT)

Analytica has a beta of 1.69, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Analytica Limited's (ASX:ALT) Earnings Dropped -12.75%, Did Its Industry Show Weakness Too?

When Analytica Limited (ASX:ALT) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … See our latest analysis for Analytica Commentary On ALT's Past Performance I prefer to use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Analytica, its latest trailing-twelve-month earnings is -AU$4.06M, which, relative to the prior year's figure, has become more negative.

Simply Wall St -

Should You Wait Before Investing In Analytica Limited (ASX:ALT)?

With a negative operating cash flow of -A$2.26M, ALT is chipping away at its A$1.21M cash reserves in order to run its business. … The cash burn rate refers to the rate at which the company uses up its supply of cash over time. … The outcome of this analysis should shed some light on ALT’s cash situation and the risks you may or may not have been aware of as a shareholder of the company.

Simply Wall St -

Company Info

Description

Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. The company’s lead product is PeriCoach system, an e-health treatment system for women who suffer stress urinary incontinence. Its PeriCoach comprises a device, Web portal, and smartphone app for evaluating activity in pelvic floor muscles. The company also provides AutoStart infusion systems to patents in the burette field. Analytica Limited is based in Brisbane, Australia.

Details
Name: Analytica Limited
ALT
Exchange: ASX
Founded:
A$13,348,049
3,337,012,350
Website: http://www.analyticamedical.com
Address: Analytica Limited
320 Adelaide Street,
Brisbane,
Queensland, 4000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ALT Ordinary Shares Australian Securities Exchange AU AUD 25. Oct 2000
CHIA ALT Ordinary Shares Chi-X Australia AU AUD 25. Oct 2000
Number of employees
Current staff
Staff numbers
0
Analytica employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 10:31
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.